Dot Medical ltd. is delighted to announce that they are now supplying EECP therapy in the UK.
Although EECP is not currently a familiar therapy to many people, Dot Medical aims to change this perception. EECP has an established research pedigree that suggests it should be the therapy of choice for the management of a wide range of medical conditions. It is non-invasive, cost effective and offers hospitals and medical staff the opportunity to treat patients on an out-patient basis and can reduce hospitalization times. This makes it extremely exciting given the current economic climate.
EECP is a non invasive therapy that helps treat heart failure by strengthening the heart muscle simply by pumping more blood back to the heart. The more blood pumped back to the heart, the stronger it gets. EECP increases blood flow to the heart by opening up collateral circulation and creating new blood vessels, while at the same time strengthening the heart. It keeps blood vessels relaxed, open and prevents plaque buildup. EECP reduces arterial stiffness and releases nitric oxide which has an antioxidant effect, making arteries resistant to spasm and clotting. It has a detoxification effect and increases lymphatic circulation.
EECP has been FDA approved since 1995 to treat coronary artery angina, cardioogenic shock and heart failure. It has had CE approval for over 10 years and is used for a wide variety of conditions including peripheral vascular disease, erectile dysfunction ( an early predictor of heart disease), sudden hearing loss and tinnitus, stroke, restless leg syndrome, peripheral neuropathy and can facilitate sports rehabilitation.
For further information contact: Dot Medical: firstname.lastname@example.org 01625 668811
This press release was distributed by ResponseSource Press Release Wire on behalf of Dot Medical in the following categories: Men's Interest, Health, Women's Interest & Beauty, Sport, Medical & Pharmaceutical, for more information visit https://pressreleasewire.responsesource.com/about.